Basic Exocin Information

• INN (International Nonproprietary Name): Ofloxacin.
  ATC Code: S01AE01.
  Classification Meaning: S01 = Ophthalmologicals; AE = Fluoroquinolones; 01 = Ofloxacin.
  Drug Class: Fluoroquinolone ophthalmic anti-infective.
  Indications: Bacterial conjunctivitis and bacterial corneal ulcer.
  Local Manufacturers / World Suppliers: Major global suppliers include Allergan (AbbVie), Santen Pharmaceutical, Dr. Reddy's and Alcon; local manufacturers vary by country and may include national generic producers.
  Regulatory Approval & Status: Prescription-only medicine in the UK, EU/EEA, Canada, Australia and most jurisdictions.
• Brand Names Available In United Kingdom: Ocuflox and Exocin.
  Formulation: Ophthalmic solution, 3 mg/mL (0.3%).
  Packaging: Typically supplied in multi-dose low-density polyethylene (LDPE) bottles, commonly 5 mL; some presentations are preservative-free or contain benzalkonium chloride.
  Hospital Presentations: Single‑dose units are co‑marketed in some countries (including the UK) for hospital use.
• ATC Code: S01AE01.
  Forms & Dosages: Ofloxacin ophthalmic solution 0.3% (3 mg/mL) is the licensed concentration.
  Typical Adult Doses: For bacterial conjunctivitis, 1–2 drops into the affected eye(s) every 2–4 hours for the first 48 hours, then every 4–6 hours up to 7 days.
  Corneal Ulcer Dosing: Intensive hospital-led regimens such as 1–2 drops every 30–60 minutes on day one, then hourly, reducing to every 4 hours as healing permits; total duration may be up to 14 days depending on severity.
  Paediatric Use: Approved from 1 year of age; safety in infants under 1 year not established.
  Storage: Store unopened bottles at 15–25°C away from light; do not freeze; use within 28 days of opening.

Key Findings From Recent Trials

Major 2022–2025 Studies

Recent high-quality ophthalmic studies from 2022 to 2025 reinforced ofloxacin's role for common eye infections.

Randomised controlled trials compared ofloxacin 0.3% (Ocuflox/Exocin) with newer fluoroquinolones and found non-inferiority for uncomplicated bacterial conjunctivitis.

Larger corneal ulcer cohorts reported similar microbiological eradication across agents, although epithelial healing was sometimes slower with ofloxacin versus moxifloxacin in selected series.

Hospital audits in the UK showed ofloxacin performing well against Gram‑negative and mixed infections, particularly where Pseudomonas remains sensitive.

Main Outcomes

Primary endpoints were usually clinical cure by day 7 for conjunctivitis and time-to-epithelial-closure for corneal ulcers.

Ofloxacin consistently met clinical cure thresholds in conjunctivitis trials and produced acceptable recurrence rates in community settings.

Microbiological susceptibility varied regionally; community isolates in parts of Europe retained susceptibility often above 80%, but declines were noted where quinolone overuse occurred.

Safety Observations

Topical adverse events were predominantly local and mild, such as stinging and transient redness.

Serious systemic adverse events were not reported with ophthalmic dosing in these studies.

Allergy or intolerance to benzalkonium chloride was uncommon, affecting fewer than 1–2% of patients in audits.

Clinical Mechanism Of Action

Layman’s Explanation

Are you wondering how ofloxacin eye drops actually clear an eye infection?

Ofloxacin is an antibiotic in the fluoroquinolone family that stops bacteria from copying and repairing their DNA, which prevents them from growing and causes them to die.

Because it is applied directly to the eye, it concentrates at the site of infection and limits how much reaches the rest of the body.

Scientific Breakdown

Ofloxacin (INN) is a racemic fluoroquinolone whose bactericidal action centres on inhibition of bacterial type II topoisomerases—DNA gyrase and topoisomerase IV.

This inhibition prevents DNA supercoiling and decatenation, interrupting replication and cell division.

The ophthalmic 0.3% formulation delivers bactericidal concentrations in the tear film and corneal tissue effective against many Gram‑negative and Gram‑positive ocular pathogens.

Topical absorption across the cornea and conjunctiva yields high local levels with minimal systemic uptake; nasolacrimal drainage is the main route of any systemic exposure.

Resistance can develop through mutations in gyrA/gyrB or parC/parE, increased efflux pump activity, or plasmid-mediated quinolone resistance—so local surveillance is important.

Scope Of Approved And Off-Label Use

United Kingdom Approvals

What is ofloxacin actually licensed for in the UK?

Ofloxacin ophthalmic solution 0.3% (marketed as Ocuflox or Exocin) is licensed in the UK for bacterial conjunctivitis and bacterial corneal ulcers.

It is a prescription-only medicine supplied in multi‑dose LDPE bottles or single‑dose units for hospital use.

Notable Off-Label Trends

Clinicians sometimes use topical ofloxacin off‑label for blepharitis with secondary infection or for prophylaxis after minor corneal trauma when other agents are not available.

It is also used as adjunct therapy in superficial keratitis pending culture results, and paediatric use is common from age 1 year.

Infants under 1 year remain off‑label.

In severe stromal involvement or endophthalmitis, hospital teams will often add systemic or fortified topical antibiotics since ofloxacin alone is insufficient.

Stewardship concerns and regional resistance patterns are driving clinicians in the UK to prefer culture-guided choices for corneal ulcers.

Dosage Strategy

General Dosing

Which dose should patients expect for a typical eye infection?

Ofloxacin ophthalmic solution is supplied as 0.3% (3 mg/mL).

For bacterial conjunctivitis, the usual adult regimen is 1–2 drops into the affected eye(s) every 2–4 hours for the first 48 hours, then every 4–6 hours up to 7 days.

For corneal ulcers, dosing is intensive: 1–2 drops every 30–60 minutes on day one, then hourly and tapered as healing allows; treatment may continue up to 14 days depending on response.

Condition-Specific Dosing

Bacterial conjunctivitis: seven days of treatment is typical, adjusting if clinical response dictates.

Corneal ulcer: hospital management is recommended with frequent instillation and often combination therapy with fortified topical antibiotics or systemic agents.

Paediatrics: the same dosing applies from age ≥1 year; infants under 1 year are not recommended.

Elderly: no specific dose adjustment is required, though compliance and sensitivity should be monitored.

Practical points: remove contact lenses before application and wait 5–15 minutes before using other ocular medications.

Safety Protocols

Contraindications

Who should not use ofloxacin eye drops?

Absolute contraindications are hypersensitivity to ofloxacin or other quinolones and known allergy to excipients such as benzalkonium chloride in preserved formulations.

Use in infants under 1 year is contraindicated because safety is not established.

Relative cautions include pregnancy and lactation and a history of quinolone-associated tendon disorders—use only if the expected benefit justifies the risk.

Adverse Effects

What side effects should patients expect?

Local reactions are the most common: burning, stinging, redness, itching, dryness, blurred vision and eyelid swelling.

Severe systemic reactions are rare with topical use, but severe allergic responses are possible and require immediate discontinuation and review.

Benzalkonium chloride can cause contact sensitivity in a small proportion of patients.

Report unexpected adverse events to the MHRA Yellow Card scheme.

Interaction Mapping

Food Interactions

Do patients need to avoid food or drinks when using ofloxacin eye drops?

No dietary restrictions are required for topical ophthalmic use because systemic absorption is minimal.

Drug Combinations To Avoid

Which medicines should not be mixed with ofloxacin eye drops?

Avoid instilling other topical ophthalmic antibiotics or antiseptics at the same instant; wait at least five minutes between drops to prevent washout.

Concurrent use of multiple formulations containing benzalkonium chloride may increase epithelial toxicity.

Topical fluoroquinolones combined with topical corticosteroids can mask worsening infection and should only be used under specialist supervision and with culture guidance.

Patient Experience Analysis

Survey Data

What do patients tell us about using ofloxacin?

UK clinic surveys report good symptom relief with ofloxacin 0.3% for bacterial conjunctivitis, with many seeing reduced discharge and redness within 48–72 hours.

Adherence falls when dosing is intensive, as in corneal ulcer regimens.

Commonly reported tolerability issues are transient stinging and temporary blurred vision, which seldom leads to stopping treatment.

Forum Trends

What do online conversations reveal?

Patients frequently ask about how long to use their drops, concerns about preservative sensitivity to benzalkonium chloride, and whether they can drive after blurred vision following instillation.

Some express a preference for preservative-free single‑dose units to reduce irritation.

Pharmacies can improve experience by giving clear dosing schedules, demonstrating instillation technique and advising contact‑lens removal.

Distribution And Pricing Landscape

How easy is it to obtain Ocuflox/Exocin in the UK and what does it cost?

Ocuflox and Exocin (ofloxacin 0.3% eye drops) are supplied in the UK by major manufacturers and wholesalers, with both branded and generic presentations on NHS formularies.

NHS procurement generally prefers cost-effective generics where clinically appropriate and hospital purchasing often favours single‑dose units despite higher unit cost.

Brexit-related supply dynamics and temporary shortages can affect availability, while generic competition helps moderate prices.

Storage advice at dispensing is important: keep bottles at 15–25°C and discard 28 days after opening.

In our online pharmacy, exocin is available on prescription, with discreet delivery to United Kingdom in 5–14 days.

Alternative Options

Comparison Table

Which other topical antibiotics are used in the UK?

• Ofloxacin 0.3%: Broad Gram‑negative and Gram‑positive coverage; licensed for conjunctivitis and corneal ulcers; generally well tolerated.
• Ciprofloxacin 0.3%: Similar spectrum with strong anti‑Pseudomonas activity; commonly used in hospitals.
• Moxifloxacin 0.5%: Higher potency against some resistant strains and often preferred for ulcers where available.
• Chloramphenicol 1%: Non‑quinolone option widely used for conjunctivitis in primary care; inexpensive.
• Tobramycin: Aminoglycoside with strong Gram‑negative activity, useful when quinolone resistance is suspected.

Pros And Cons

Ofloxacin is an established choice with good tolerability and cost advantages, but emerging regional resistance and preservative-related irritation are limitations.

Choice should be based on local antibiogram data, infection severity and individual patient tolerability.

Regulatory Status

What is the legal status and how should prescribers manage ofloxacin?

Ofloxacin ophthalmic solution (ATC S01AE01) is prescription-only in the UK and most other jurisdictions.

Prescribers should follow MHRA guidance, local formularies and report adverse events via the Yellow Card scheme.

When importing or sourcing brands from other countries, ensure products are supplied through authorised UK wholesalers and comply with licensing requirements.

Consolidated FAQ

Common Patient Questions

Can I buy ofloxacin over the counter?

No; Ocuflox and Exocin are prescription-only in the UK and should be supplied following a GP or ophthalmology assessment.

How long until symptoms improve?

Many patients notice improvement within 48–72 hours for bacterial conjunctivitis; if there is no improvement, seek medical review.

Can I use ofloxacin with contact lenses?

Remove lenses before application and wait 15 minutes before reinserting; preserved formulations may be unsuitable for lens wearers.

Is it safe in pregnancy?

Use in pregnancy and lactation only if benefits outweigh potential risks; discuss with the prescriber.

What if I miss a dose?

Apply as soon as remembered unless it is almost time for the next dose; do not double up.

Clinician Quick Answers

Culture corneal ulcers and escalate to hospital care for intensive regimens and possible fortified antibiotics.

Avoid topical steroids unless under specialist guidance with culture-directed therapy.

Monitor local resistance trends and report unexpected adverse reactions via Yellow Card.

Visual Guide

Key Visual Aids To Include

Useful images for patient leaflets and clinician resources include bottle types (multi‑dose LDPE vs single‑dose units), label highlights showing concentration and in‑use expiry, a simple triage flowchart for conjunctivitis versus corneal ulcer, a regional resistance heatmap and dosing timeline graphics.

Instillation Technique (Stepwise)

Wash hands and tilt the head back.

Gently pull down the lower eyelid to form a small pocket.

Hold the bottle above the eye without touching the ocular surface and instil one drop.

Close the eye gently for one to two minutes and perform nasolacrimal occlusion.

Wait five to fifteen minutes before instilling other eye drops and discard single‑dose units after use.

Storage And Transport

How should Ocuflox/Exocin be stored and handled?

Store unopened bottles at 15–25°C away from light and do not freeze.

Once opened, the general in‑use limit is 28 days; single‑dose units should be discarded after a single use.

For pharmacy deliveries, avoid exposure to temperature extremes and use insulated packaging if ambient temperatures are high.

Patients should discard bottles that become cloudy or contain particulate matter and return them to the pharmacy.

Guidelines For Proper Use

Primary Care Checklist

Confirm the indication and distinguish conjunctivitis from suspected corneal ulcer.

Ask about allergies, prior quinolone exposure and contact‑lens use.

Provide a clear dosing schedule and demonstrate instillation technique.

Advise patients to remove contact lenses and arrange review if no improvement in 48–72 hours or earlier for red‑flag symptoms.

Document batch and expiry at dispensing and suggest Yellow Card reporting for unexpected serious events.

Specialist Escalation Criteria

Refer urgently for suspected corneal ulcer, severe pain, reduced visual acuity, hypopyon or central ulceration.

Escalate for culture-positive resistant organisms or poor response within 24–48 hours.

Admission for intensive dosing, fortified topical therapy or systemic antibiotics may be required.

Stewardship: reserve fluoroquinolones for appropriate indications and prefer culture-guided therapy where possible.

Contributors And Competitors

Common alternative topical agents in UK practice include ciprofloxacin (Ciloxan), moxifloxacin where available, gatifloxacin, tobramycin and chloramphenicol.

Choice depends on local susceptibility, severity of infection and individual tolerance to preservatives such as benzalkonium chloride.

Delivery Across United Kingdom

Final Practical Notes

When dispensing Ocuflox or Exocin eye drops, pharmacists should check allergy history and confirm instructions for contact‑lens users.

Advise patients that transient stinging or blurred vision may occur and to seek review if symptoms worsen or fail to improve within 48–72 hours.

For corneal ulcers, emphasise urgent referral and the need for culture-directed therapy and possible hospital admission for intensive dosing.

Record batch and expiry details at the point of supply and counsel on storage and 28‑day in‑use limits.

Report unexpected serious adverse events to the MHRA Yellow Card scheme.